{"doi":"10.1093/neuonc/noae165.0432","title":"CTNI-65. DETERMINANTS OF LONG-TERM SURVIVAL IN PATIENTS WITH IDH-MUTANT GLIOMAS","abstract":"Abstract BACKGROUND Survival times of patients with IDH-mutant gliomas is variable and can extend to decades. Many studies only provide progression-free rather than overall survival times and prognostic factors remain ill-defined. Here we explored clinical disease characteristics of long-term survivors within a large cohort of patients with extended follow-up. METHODS This single-center, retrospective analysis included 114 patients with IDH-mutant glioma that either died due to tumor-related causes or survived at least 15 years after first diagnosis. Patient characteristics, outcomes, and prognostic factors were stratified by short- (< 15 years) versus long-term (≥ 15 years) survival. Initial diagnosis was (re-)classified according to the WHO 2016 classification. Uni- and multivariate analyses were performed. RESULTS Overall, 66 patients (58%) were diagnosed with astrocytoma and 48 patients (42%) with oligodendroglioma. Median follow-up of the survivors was 16.6 years (range 15-28.9). 62 tumor-related deaths (54%) had been reported at database closure. Patients that died before reaching 15 years survival time had been diagnosed with astrocytoma in 41 (72%) and oligodendroglioma in 16 cases (28%). The long-term survivor cohort comprised 25 patients (44%) with astrocytoma and 32 patients (56%) with oligodendroglioma. Long-term survival was associated with grade 2 histology (p < 0.01), smaller tumor volumes (p < 0.01), and lack of contrast enhancement (p = 0.02). 41 long-term survivors (72%) were initially monitored by a wait-and-scan strategy as opposed to 16 patients (28%) in the cohort of short-term survival (p<0.01). In patients with oligodendroglioma, a higher KPS was associated with longer survival (HR 0.25; 95% CI 0.02-0.67; p = 0.05). Tumor resection (HR 0.43; 95% CI 0.22-0.86; p = 0.02) and wait-and-scan strategies (HR 0.34; 95% CI 0.14-0.79; p = 0.01) were associated with longer survival in patients with astrocytoma. CONCLUSION Tumor resection followed by a wait-and-scan strategy may yield excellent survival times, especially in patients with IDH-mutant grade 2 astrocytoma. Age appears not be an important predictor for survival in patients with IDH-mutant gliomas.","journal":"Neuro-Oncology","year":2024,"id":505951,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8338,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1356997,"name":"Jonathan Weller","orcid":"0000-0001-6013-8069","position":1,"is_corresponding":false},{"id":1356998,"name":"Sebastian Niedermeyer","orcid":"0000-0003-2647-7256","position":2,"is_corresponding":false},{"id":1356999,"name":"Jens Blobner","orcid":"0000-0002-8539-8745","position":3,"is_corresponding":false},{"id":1357290,"name":"Christoph Trumm","orcid":null,"position":4,"is_corresponding":false},{"id":1357291,"name":"Rupert Egensperger","orcid":null,"position":5,"is_corresponding":false},{"id":695077,"name":"Patrick N. Harter","orcid":"0000-0001-5530-6910","position":6,"is_corresponding":false},{"id":1357000,"name":"Louisa von Baumgarten","orcid":"0000-0002-6634-0927","position":7,"is_corresponding":false},{"id":264179,"name":"Veit M. Stoecklein","orcid":"0000-0001-6206-0621","position":8,"is_corresponding":false},{"id":1357292,"name":"Joerg-Christian Tonn","orcid":null,"position":9,"is_corresponding":false},{"id":7227,"name":"Michael Weller","orcid":"0000-0002-1748-174X","position":10,"is_corresponding":false},{"id":264184,"name":"Niklas Thon","orcid":"0000-0003-0011-5281","position":11,"is_corresponding":false},{"id":1356996,"name":"Sophie Katzendobler","orcid":"0000-0002-9762-7955","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:10:50.984927Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}